Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545440 | 1.00 | AOC3 (0.35) | AOC3GLSCYP17A1MEN1KMT2A | |
| SCHEMBL4867227 | 0.89 | GLS (0.41) | AOC3GLSCYP17A1 | |
| SCHEMBL4867217 | 0.89 | GLS (0.41) | AOC3GLSCYP17A1 | |
| SCHEMBL4867330 | 0.89 | GLS (0.41) | AOC3GLSCYP17A1 | |
| SCHEMBL3931434 | 0.87 | AOC3 (0.37) | AOC3GLSCYP17A1 | |
| SCHEMBL3931429 | 0.87 | AOC3 (0.37) | AOC3GLSCYP17A1 | |
| SCHEMBL3931427 | 0.87 | AOC3 (0.37) | AOC3GLSCYP17A1 | |
| SCHEMBL5545437 | 0.84 | AOC3 (0.35) | AOC3MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL4875952 | 0.84 | AOC3 (0.39) | AOC3GLSCYP17A1MEN1KMT2A | |
| SCHEMBL4875960 | 0.84 | AOC3 (0.39) | AOC3GLSCYP17A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885GLS 3831/4885CYP17A1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.